Navigation Links
Experimental Pill for Multiple Sclerosis Shows Promise
Date:4/16/2012

milar safety concerns may arise with this drug, Birnbaum said.

"In addition, the drug induces a lymphopenia [low white blood cell count], indicating it too is an immune suppressant. Immune suppression has its own dangers, as noted with fingolimod, where two patients died of liver infections, and there was an increased risk of skin cancer," Birnbaum said.

More study is needed to assess the long-term effectiveness and safety of ONO-4641, he said.

"At first glance, the drug appears to reduce central nervous system inflammation, but data on reducing [MS] disease progression and long-term safety will be needed to assess the final value of this drug," Birnbaum said.

For the trial, investigators randomly assigned 407 people aged 18 to 55 with relapsing-remitting MS to one of three daily doses of the drug or placebo. Patients underwent brain scans once every month between weeks 10 and 26 of treatment.

After 26 weeks, Vollmer's group found that compared to those taking a placebo, patients on the low dose of ONO-4641 experienced an average 82 percent reduction in what experts call "MS-enhancing brain lesions."

For those receiving the middle dose the reduction was 92 percent and for those on the high dose, 77 percent, they found.

Adverse events were related to the dose of the drug patients received and included cardiovascular events such as a slower heartbeat, blood pressure changes or other heart problems.

Other side effects included liver-enzyme elevations. In addition, lymphopenia occurred in 4 percent of people receiving the high dose of ONO-4641 and in 1 percent of those receiving the middle dose, the researchers note.

The study was supported by the drug's maker, Ono Pharmaceutical Co., Ltd.

Another expert, Nicholas LaRocca, vice president for health care delivery and policy research at the National MS Society, said that "MS is a complex disease that affects each person differently and so it is import
'/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. Experimental Chemo Combo for Colon Cancer Disappoints
2. Experimental Pill May Ease Multiple Sclerosis Disability
3. Experimental Drug Shows Promise Against Cushings Disease
4. Experimental Drug Offers Hope for Rare Bone Disease: Study
5. Experimental Drug Shows Promise Against Type 2 Diabetes
6. First-in-human drug for malignant glioma available in experimental trial
7. Experimental Drug Might Beat Aspirin in Preventing Repeat Strokes: Study
8. Experimental Drugs Do Battle Against Advanced Prostate Cancer
9. Experimental Blood Thinner Given Before Surgery Shows Benefit
10. Wolfson Foundation awards £20 million to UCL for experimental neurology center
11. Novel experimental agent is highly active in CLL patients, interim study shows
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Experimental Pill for Multiple Sclerosis Shows Promise
(Date:9/2/2014)... 02, 2014 With recent expansions to their ... to create a consistent look or specific ambiance that tells ... floor you walk on and the chair you sit in, ... wood designs. , “We’re excited to offer a more ... It saves time, adds consistency, and let’s not forget celebrates ...
(Date:9/2/2014)... Cleveland, Ohio (PRWEB) September 02, 2014 ... Cellulon® Polyurethane technology to reduce discomfort and fatigue by ... flooring. Using an eco-friendly, renewable bio-foam core, these anti-fatigue ... in the USA. According to a study by the ... showing a significant difference in reducing spinal compression and ...
(Date:9/2/2014)... white pill may help scientists learn why patients with ... even if their lungs are relatively healthy. , ... Revatio to treat pulmonary hypertension and Viagra for erectile ... antioxidants will help them identify the root of the ... patients. , "We want to understand why these ...
(Date:9/2/2014)... of opioid-involved overdoses has become an increasing concern to ... the New York City Department of Health and Mental ... 2011 was nearly triple the number of such deaths ... to a dramatic rise in nonmedical prescription opioid (PO) ... in heroin use among youth who transitioned from POs ...
(Date:9/2/2014)... 2014In a new guideline, the Society for Maternal-Fetal Medicine ... in pregnancy. , "There is no evidence that ... of Delaware Center for Maternal and Fetal Medicine and ... is evidence that bed rest can be harmful for ... five women are placed on bed rest during their ...
Breaking Medicine News(10 mins):Health News:Pioneer Millworks Now Offering Products Beyond Reclaimed Wood Flooring 2Health News:New Eco-Pro Premium Anti-fatigue Mats from Martinson-Nicholls Prevent Fatigue and Discomfort for Standing Workers 2Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 2Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 3Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 4Health News:NYC teens and young adults who abuse prescription at high risk for overdose 2Health News:NYC teens and young adults who abuse prescription at high risk for overdose 3Health News:SMFM releases paper on activity restriction in pregnancy 2
... saves a life. Saturday, April 25 is World Malaria Day. , ... ... teaming up with the United Nations Foundation and its Nothing But Nets ... his New Look Foundation, Raymond and the UN Foundation will provide opportunities ...
... | About 400 cancer therapy specialists from 100 countries ... week in Vienna at an IAEA event to discuss modern ... Conference on Advances in Radiation Oncology (ICARO) will start on ... the Vienna International Center. , All sessions of the ...
... Medical Technologies, Inc. (Nasdaq: PMTI ), a leading ... hold its quarterly conference call of its 2009 first quarter ... Eastern Time. If you would like to participate, please call ... The telephone replay will be available one hour after the ...
... Addicts, even those who have been abstinent for long ... memories of prior drug use. For example, exposure to ... a contextual memory can increase their craving for the ... study in the April 15th issue of Biological Psychiatry ...
... CINCINNATI, April 23 Kendle (Nasdaq: KNDL ... quarter 2009 financial results after the market closes on ... telephone conference call and simultaneous webcast on Thursday, May ... answer session will follow.(Logo: http://www.newscom.com/cgi-bin/prnh/20080923/CLTU095LOGO ...
... PALO ALTO, Calif., April 23 Percutaneous Systems, Inc. ... Accordion CoAx(TM) Stone Control Device, the newest member ... tools, at the upcoming annual meeting of the American ... Chicago, Illinois.The Accordion CoAx Stone Control Device is an ...
Cached Medicine News:Health News:IAEA conference to focus on new techniques in cancer treatment 2Health News:Palomar Medical Technologies to Host First Quarter 2009 Financial Results Conference Call and Webcast on April 30, 2009 2Health News:Treating addiction by eliminating drug-associated memories 2Health News:Kendle Announces First Quarter 2009 Earnings Conference Call and Webcast 2Health News:PercSys Introduces Accordion CoAx(TM) Stone Control Device for Facilitating Percutaneous Kidney Stone Treatments 2Health News:PercSys Introduces Accordion CoAx(TM) Stone Control Device for Facilitating Percutaneous Kidney Stone Treatments 3
(Date:9/2/2014)... September 2, 2014 , ... 2014 provide insight into treatment and outcomes of ... practice --   Data from nearly ... in the FIELD-Atrial Fibrillation (GARFIELD-AF), an innovative, independent ... strategies for atrial fibrillation (AF) patients remain sub-optimal ...
(Date:9/2/2014)... , Sept. 2, 2014 /PRNewswire-iReach/ -- Ortho Development® Corporation ... Hip Stem, the latest addition to its growing ... is intended for use in total hip arthroplasty ... http://photos.prnewswire.com/prnh/20140830/141676 Alpine was developed ... philosophy. ODEV,s engineers worked closely with a select ...
(Date:9/2/2014)... , Sept. 2, 2014  PANTHERx Specialty ... Specialty Pharmacy Accreditation from URAC, a ... that establishes quality standards for the health care ... The URAC accreditation process demonstrates ... a framework to improve business processes through benchmarking ...
Breaking Medicine Technology:Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 2Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 3Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 4Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 5Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 6Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 7Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 8Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 9Ortho Development Receives FDA Clearance for Alpine Hip Stem 2PANTHERx Specialty Pharmacy Applying for URAC Specialty Pharmacy Accreditation 2
... DEERFIELD, Ill. , April 28 ... and its wholly owned subsidiary, Takeda Pharmaceuticals North America, ... of eight defendants in patent infringement litigation brought against ... Applications ("ANDAs") for generic ACTOS® (pioglitazone HCl) and ACTO ...
... Texas , April 27 Lexicon Pharmaceuticals, ... on discovering and developing breakthrough treatments for human disease, announced ... presentations on results from its Phase 2 clinical study with ... (IBS) at Digestive Disease Week (DDW) 2010 in New ...
Cached Medicine Technology:Takeda Provides Update on Patent Litigation for ACTOS(R) (pioglitazone HCl) and ACTOplus met(R) (pioglitazone HCl and metformin HCl) in the U.S. 2Takeda Provides Update on Patent Litigation for ACTOS(R) (pioglitazone HCl) and ACTOplus met(R) (pioglitazone HCl and metformin HCl) in the U.S. 3Takeda Provides Update on Patent Litigation for ACTOS(R) (pioglitazone HCl) and ACTOplus met(R) (pioglitazone HCl and metformin HCl) in the U.S. 4Takeda Provides Update on Patent Litigation for ACTOS(R) (pioglitazone HCl) and ACTOplus met(R) (pioglitazone HCl and metformin HCl) in the U.S. 5Takeda Provides Update on Patent Litigation for ACTOS(R) (pioglitazone HCl) and ACTOplus met(R) (pioglitazone HCl and metformin HCl) in the U.S. 6Takeda Provides Update on Patent Litigation for ACTOS(R) (pioglitazone HCl) and ACTOplus met(R) (pioglitazone HCl and metformin HCl) in the U.S. 7Takeda Provides Update on Patent Litigation for ACTOS(R) (pioglitazone HCl) and ACTOplus met(R) (pioglitazone HCl and metformin HCl) in the U.S. 8Lexicon to Present Phase 2 Clinical Data for IBS Drug Candidate at Digestive Disease Week 2Lexicon to Present Phase 2 Clinical Data for IBS Drug Candidate at Digestive Disease Week 3
... DTX Series Multimode Detectors provide unmatched ... of application and automation needs. Capable ... measurements on the same instrument, the ... instruments or can be integrated seamlessly ...
... PCR, cDNA and Oligonucleotides The Tecan ... a variety applications that are quantified by Fluorescence, ... handle assays in Microplate formats from 6 ... Cuvettes Independent whether you have to ...
... Designed for Ultra High Throughput Screening ... assay detection performance. Allows for smooth ... assay development by sharing all the ... HT, fluorescence intensity, fluorescence polarization, time-resolved ...
... system used to detect and quantitate contaminants, ... cell protein, bovine contaminants (e.g., BSA, IgG, ... any unique protein that can be bound ... and plasmid copy number. The system reduces ...
Medicine Products: